Clinical trial
Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory…
NCT00259818 · Erimos Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00259818 |
|---|---|
| Title | Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors |
| Official title | An Open-Label Phase I Dose Escalation Study of Intravenous Infusion of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Refractory Malignant Tumors |
| Lead sponsor | Erimos Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | EM-1421 |
| Enrollment | 30 |
| Start date | Dec 1, 2005 |
| Completion | Jan 1, 2008 |
| First posted | Dec 1, 2005 |
| Last update posted | Jan 24, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: